>Lead / advise on all transactions, deal structuring, and negotiations in addition to end business development lifecycle from search/evaluation, term sheets, contract negotiations to post transaction alliance management>Create, implement, and lead the company’s businesses development and strategic initiatives>Lead and own late-stage / transformative “needle-mover” transaction process

> Established in 1962, the Youth Science Center (YSC) is a non-profit organization dedicated to improving math and science education (STEM education programs)> Advice on educational programs, lead fundraising activities, and advise on operations

> Lead, evaluate and execute complex transactions & corporate strategy initiatives to refine and achieve specific corporate development goals across global/regional, commercial, sales & marketing, R&D, and therapeutic area targets> Draft term sheets, lead negotiation strategies and manage external partners through deal execution> Lead and own various stages of transaction execution process, from strategy development to integration, including technical and financial due-diligence, negotiations, valuation, financial impact (adjusted / GAAP / IFRS), executive communications, legal contracting review, and press releases > Design deal structures for in/out licensing, M&A, tax-free spin-outs, divestiture, strategic distribution as deemed necessary> Business partner to Region Europe/Russia, LatAM and JAPAC on all commercial stage deals

> Assisted leadership in execution of key initiatives, projects and business development that impacts the firm’s West Coast business performance overall> Design, review and evaluate transaction structures, terms sheets, legal contracts, and economic / valuation outcomes as lead transactions advisor(s), in corporate strategy planning needs, through negotiations (i.e. scripting, strategy), and for compliance document (i.e. fairness opinions, audit requirements) filing process in transactions life-cycle> Manage (train and develop) a team of analysts and associates with respect to valuations for various purposes such as, consulting, merger and acquisitions, financial and tax reporting requirements> Manage relationships with key internal and external clients such as CFOs, controllers, auditors of small privately-held companies to large Fortune 500 companies in industries such as: Private Equity, Venture Capital, Energy, Aerospace, Medical Devices, Biotechnology, and Manufacturing

> Advised clients on the value and opportunity of their business for corporate development, corporate strategy, M&A, financial reporting, tax restructuring, performance improvement, working capital management and divestiture purposes. > Through EY Capital Advisory and partnering with Law Firms, lead transaction structure design, draft bid letters/terms sheets, review and evaluate economic impacts of legal contract terms and prepare scripts for negotiations on complex transaction / M&A engagements > Assisted leadership in quality risk management initiatives, go-to-market strategy, and new business development as an elected committee member to the National Valuation Quality Risk Management Committee (EY North America, Central America & India)> Mentored and managed staff and associates > Created training & development programs and organized various charity events for corporate development and brand awareness purposes

> Sell-side/Buy-side consulting services for corporate development transaction design, legal contract review/evaluation, and tax planning needs> Prepare negotiation scripting and deposition documents for transactions in M&A, tax, accounting and dispute situations> Focused on Private Equity & Hedge Fund interests, Life Science, Biotechnology, and Healthcare Service Company valuations > Valuation Services in: Estate & Gift Tax Reporting, Purchase Price Allocation (ASC 805) and Goodwill Impairment (ASC 350), Fair Value, Measurements For Hedge Funds and Private Equity Assets (ASC 820), Employee Stock Ownership Plans (ESOPs), Option Pricing & Restricted Stock, Fairness Opinions, Intellectual Property, Litigation Support, and Speaker Services

> Initiated research coverage on six U.S. large-cap biopharma companies (ACOR, AMGN, BIIB, CELG, GILD, HGSI), during the changeover period from Thomas Weisel to Stifel Nicolaus> Built and maintained complex valuation models, DCF forecasts, clinical data analytics and Pitch Books

> ITT Corporation (NYSE: ITT): Designed, tested and launched an analytics tool to manage transportation logistics, costs, and throughput of over 25,000 waste & wastewater treatment facilities in 30 U.S. States, as a part of a pilot program to a £220M opportunity spin off Xylem, Inc. (NYSE: XYL), using Google Earth, MS Access, Excel and Visio> McKesson (NYSE: MCK): Proposed an existing product combination as a new pharmacy automation system to capture a niche market and ensure better return on investment. The division was spun off in 2013 as Aesynt, Inc.

> A Johnson & Johnson family of companies (spun off private in 2013)> Hired, transformed and led cross-functional teams of scientists to acquire over 330,000 clinical specimens and test fluids in less than 8 months to complete verification/validation studies (510k), resulting in 30% savings in allocated budget, in a $1.7B medical device product launch initiative> Acted as the liaison for divisional directors in the US, the UK, and Japan during the FDA approval/launch process > Recipient: J&J Encore Award (Platinum Level): Highest honors for outstanding project management skills(On a consultative basis from Jan. through May 2009, while attending business school)

> Enterprise business venture between the Russian Federation and Sri Lanka, which involved education consulting services and raw material export/import